Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zika Hearing Shows How Vaccine Timelines Are Outbreak-Dependent

This article was originally published in The Pink Sheet Daily

Executive Summary

NIAID appears on track to have Zika vaccine in widespread testing in late 2017, but development depends in part on the epidemic rate; additional funding is necessary to respond to the outbreak, NIAID director and CDC official testify at Senate and House hearings.

Advertisement

Related Content

Zika Vaccines Might Be Approved By 2020
Zika Vaccine Trials Could Test Multiple Candidates Vs. Common Control Group

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS079147

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel